Showing results (21-30 of 756) with videos related to

Sort By:
Pageof 76
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, et al.
The Lancet. Gastroenterology & Hepatology|January 20, 2022
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel DiseasesLucas Guillo, Maria Abreu, Remo Panaccione, et al.
The Lancet. Gastroenterology & Hepatology|November 25, 2021
Update on the mesentery: structure, function, and role in diseaseJ Calvin Coffey, Kevin G Byrnes, Dara John Walsh, et al.
The Lancet. Gastroenterology & Hepatology|November 5, 2021
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trialHenit Yanai, Arie Levine, Ayal Hirsch, et al.
The Lancet. Gastroenterology & Hepatology|November 3, 2022
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)Choong-Kun Lee, Hong Jae Chon, Jaekyung Cheon, et al.
The Lancet. Gastroenterology & Hepatology|January 9, 2022
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trialXiangrui Meng, Tao Wu, Yonggui Hong, et al.
The Lancet. Gastroenterology & Hepatology|September 24, 2022
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trialSimon Mark Dahl Baunwall, Sara Ellegaard Andreasen, Mette Mejlby Hansen, et al.
The Lancet. Gastroenterology & Hepatology|May 19, 2019
Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trialYasuhide Yamada, Narikazu Boku, Junki Mizusawa, et al.
The Lancet. Gastroenterology & Hepatology|May 25, 2019
The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatmentDavid J Gracie, P John Hamlin, Alexander C Ford
The Lancet. Gastroenterology & Hepatology|July 30, 2018
Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trialShin Fukudo, Yuka Endo, Michio Hongo, et al.
Pageof 76